All In Biotech

Drug Trial Radar · NCT07124117

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-902 in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

147

Planned (sponsor's estimate)

Start

Aug 4, 2025

Primary completion

Feb 8, 2029

Study completion Feb 8, 2029

Sponsor

Lead sponsor
OBI Pharma, IncIndustry
Sponsor type
Industry
First posted
Aug 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safety and preliminary antitumor activity of the putative RP2D of OBI-902 in selected tumor types. Phase 2 (Randomized Dose Optimization Cohorts) is intended to determine the optimal RP2D of OBI-902 in selected tumor types, before advancing to larger Phase 3 trials.

Conditions

  • Advanced Solid Tumor

Interventions

  • OBI-902Drug

    OBI-902 is an antibody-drug conjugate study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of OBI-902: incidence of adverse events (AEs) and serious adverse events (SAEs), changes in selected clinical laboratory parameters, cardiac parameters, and vital signs.Time frame: Duration of study, up to 54 weeks
  2. Maximum tolerated dose (MTD) of OBI-902Time frame: Duration of study, up to 54 weeks
  3. Preliminary antitumor activity of OBI-902 in selected tumor types - Objective Response Rate (ORR)Time frame: Duration of study, up to 54 weeks
  4. Preliminary antitumor activity of OBI-902 in selected tumor types - Duration of Response (DoR)Time frame: Duration of study, up to 54 weeks
  5. Preliminary antitumor activity of OBI-902 in selected tumor types - Clinical Benefit Rate (CBR)Time frame: Duration of study, up to 54 weeks
  6. Preliminary antitumor activity of OBI-902 in selected tumor types - Disease Control Rate (DCR)Time frame: Duration of study, up to 54 weeks
  7. Safety and tolerability of OBI-902 in Phase 1b/Phase 2: incidence of AEs, SAEs, and laboratory abnormalities.Time frame: Duration of study, up to 54 weeks
  8. Optimal recommended phase 2 dose (RP2D) of OBI-902Time frame: Duration of study, up to 54 weeks

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Scripps Green Hospital

    La Jolla, California · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • China Medical University Hospital

    Taichung, Taiwan · Recruiting

  • Wan Fan Hospital

    Taipei, Wenshan, Taiwan · Recruiting

  • Shuang Ho Hospital

    Taipei, Zhonghe, Taiwan · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.